Not all of the Twitter trolls who stormed the place after Elon Musk took over end up the bad guys. Amongst the domestic terrorists, there have been a few disruptors who’s mischief seemed to be aimed at hitting Musk where it would hurt most—with Twitter advertisers. That they could make the massive corporations that were their target feel some pain, too, was gravy.
Case in point, the fake tweet that was heard ‘round the world: fake Eli Lilly tweeting, “We are excited to announce insulin is free now.” The tweet was up for at least four hours and was seen by millions before Twitter could take it down and lock down the fake account. The real Eli Lilly account eventually posted a message saying, “We apologize to those who have been served a misleading message from a fake Lilly account. Our official Twitter account is @LillyPad.” That was a mistake.
Outrage ensued, with people yelling at the company for apologizing for a fake tweet that was not in their control instead of acknowledging and apologizing for price gouging on a life-saving and cheap-to-produce drug. That included Sen. Bernie Sanders, who wrote that the company “should apologize for increasing the price of insulin by over 1,200% since 1996 to $275 while it costs less than $10 to manufacture.”
Campaign Action
The outrage actually got a response: this grudging admission from Eli Lilly CEO David Ricks that all those furious people have a point. “It probably highlights that we have more work to do to bring down the cost of insulin for more people,” Ricks said. Yes, it does do that.
But Ricks didn’t entirely get the point, blaming “federal rules” for unaffordable insulin even for people who have health insurance. “Those are the cases that produce the outrage, and understandably,” Ricks said. “We want to do our part and work with payers in the system to provide copay assistance. We’re open to feedback [on improving communications],” he said. “We’ve done tons of things, but it obviously hasn’t penetrated the clutter. We’re obviously not the only insulin company. But the tropes go on.”
It’s not a communications problem. It’s a greed problem, and it is a uniquely American problem. A 2018 study from BMJ Global Health estimates the cost to produce a vial of insulin from between $2 for regular human insulin to less than $7 for newer analogs, like the Lispro analog Eli Lily produces. The list price for that analog is $274.70 per 10 mL vial. Eli Lilly offers a generic version at $82.41 per vial. That’s what any objective observer would call price gouging.
The RAND Corporation 2018 study demonstrated that the cost of insulin to diabetics in the U.S. is generally five to 10 times higher than in the other OECD countries (Organization for Economic Co-operation and Development). Where the 2018 average price per vial was less than $10 for other OECD patients, it was just under $100 for U.S. patients. That’s before insurance co-pays, rebates, and discounts are applied, which can bring the out-of-pocket cost for a U.S. patient down to just four times what another OECD national would pay.
Again, that’s not a communication problem. That’s a price gouging problem, and yes, federal regulation plays a role and has for decades. Federal laws and regulations have allowed Big Pharma to set the terms. Corporate greed took care of the rest. Ricks isn’t going to acknowledge that, but at least he had to feel some heat for it.
We beat back the so-called Red Wave, but our job is not done. Daily Kos is determined to help us win Georgia, and is pouring resources. Please donate $5 today
Election 2022 is officially in overtime, with a Georgia Runoff. We must get out every last Democratic voter for Raphael Warnock. Click here to volunteer in whatever way possible you can.
RELATED STORIES
$35 insulin caps for Medicare patients is not enough: Advocates want price caps across the board
Republicans could have helped Democrats save the lives of diabetics. They refused
House Democrats vote to make insulin affordable for people with insurance, 193 Republicans oppose it
Once again, Senate Republicans prove how little they really care about life
We're now in the second week of election overtime and there are still plenty of major races yet to be decided—as well as tons more great news for Democrats to exult over on this week's episode of The Downballot. On the uncalled races front, co-hosts David Nir and David Beard dive into a pair of House races in California and several legislatures that could flip from red to blue, including the Pennsylvania House. Speaking of legislatures, the Davids also go deep on what the astonishing flips in Michigan will mean for progressives and particularly organized labor.
Embedded Content
Case in point, the fake tweet that was heard ‘round the world: fake Eli Lilly tweeting, “We are excited to announce insulin is free now.” The tweet was up for at least four hours and was seen by millions before Twitter could take it down and lock down the fake account. The real Eli Lilly account eventually posted a message saying, “We apologize to those who have been served a misleading message from a fake Lilly account. Our official Twitter account is @LillyPad.” That was a mistake.
Outrage ensued, with people yelling at the company for apologizing for a fake tweet that was not in their control instead of acknowledging and apologizing for price gouging on a life-saving and cheap-to-produce drug. That included Sen. Bernie Sanders, who wrote that the company “should apologize for increasing the price of insulin by over 1,200% since 1996 to $275 while it costs less than $10 to manufacture.”
Campaign Action
The outrage actually got a response: this grudging admission from Eli Lilly CEO David Ricks that all those furious people have a point. “It probably highlights that we have more work to do to bring down the cost of insulin for more people,” Ricks said. Yes, it does do that.
But Ricks didn’t entirely get the point, blaming “federal rules” for unaffordable insulin even for people who have health insurance. “Those are the cases that produce the outrage, and understandably,” Ricks said. “We want to do our part and work with payers in the system to provide copay assistance. We’re open to feedback [on improving communications],” he said. “We’ve done tons of things, but it obviously hasn’t penetrated the clutter. We’re obviously not the only insulin company. But the tropes go on.”
It’s not a communications problem. It’s a greed problem, and it is a uniquely American problem. A 2018 study from BMJ Global Health estimates the cost to produce a vial of insulin from between $2 for regular human insulin to less than $7 for newer analogs, like the Lispro analog Eli Lily produces. The list price for that analog is $274.70 per 10 mL vial. Eli Lilly offers a generic version at $82.41 per vial. That’s what any objective observer would call price gouging.
The RAND Corporation 2018 study demonstrated that the cost of insulin to diabetics in the U.S. is generally five to 10 times higher than in the other OECD countries (Organization for Economic Co-operation and Development). Where the 2018 average price per vial was less than $10 for other OECD patients, it was just under $100 for U.S. patients. That’s before insurance co-pays, rebates, and discounts are applied, which can bring the out-of-pocket cost for a U.S. patient down to just four times what another OECD national would pay.
Again, that’s not a communication problem. That’s a price gouging problem, and yes, federal regulation plays a role and has for decades. Federal laws and regulations have allowed Big Pharma to set the terms. Corporate greed took care of the rest. Ricks isn’t going to acknowledge that, but at least he had to feel some heat for it.
We beat back the so-called Red Wave, but our job is not done. Daily Kos is determined to help us win Georgia, and is pouring resources. Please donate $5 today
Election 2022 is officially in overtime, with a Georgia Runoff. We must get out every last Democratic voter for Raphael Warnock. Click here to volunteer in whatever way possible you can.
RELATED STORIES
$35 insulin caps for Medicare patients is not enough: Advocates want price caps across the board
Republicans could have helped Democrats save the lives of diabetics. They refused
House Democrats vote to make insulin affordable for people with insurance, 193 Republicans oppose it
Once again, Senate Republicans prove how little they really care about life
We're now in the second week of election overtime and there are still plenty of major races yet to be decided—as well as tons more great news for Democrats to exult over on this week's episode of The Downballot. On the uncalled races front, co-hosts David Nir and David Beard dive into a pair of House races in California and several legislatures that could flip from red to blue, including the Pennsylvania House. Speaking of legislatures, the Davids also go deep on what the astonishing flips in Michigan will mean for progressives and particularly organized labor.
Embedded Content